Drug Insight: different mechanisms of action of tumor necrosis factor antagonists—passive-aggressive behavior?

被引：0

作者：

William FC Rigby

机构：

[1] WFC Rigby is a Professor of Medicine,

[2] Microbiology and Immunology at Dartmouth Medical School,undefined

[3] Lebanon,undefined

[4] NH,undefined

[5] USA.,undefined

来源：

Nature Clinical Practice Rheumatology | 2007年 / 3卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Etanercept, adalimumab and infliximab all specifically antagonize tumor necrosis factor (TNF), but with differential clinical efficacy. Differences in their pharmacology and mechanisms of action, and disease heterogeneity, might account for this therapeutic disparity, as might reverse signaling by transmembrane TNF in response to anti-TNF antibodies, all of which are reviewed here.

引用

页码：227 / 233

页数：6

共 50 条

[31] Optimizing Therapeutic Drug Monitoring of Tumor Necrosis Factor-α Antagonists in Patients With Inflammatory Bowel Diseases
Cui, Dejun
Hu, Mei
Zhao, Xun
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (10) : 1509 - 1509
[32] Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease
Pan, Yushan
Ahmed, Waseem
Mahtani, Prerna
Wong, Rochelle
Longman, Randy
Lukin, Dana Jeremy
Scherl, Ellen J.
Battat, Robert
INFLAMMATORY BOWEL DISEASES, 2022, 28 (12) : 1865 - 1871
[33] A Safety Assessment of Tumor Necrosis Factor Antagonists During Pregnancy: A Review of the Food and Drug Administration Database
Carter, John D.
Ladhani, Anil
Ricca, Louis R.
Valeriano, Joanne
Vasey, Frank B.
JOURNAL OF RHEUMATOLOGY, 2009, 36 (03) : 635 - 641
[34] Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism -: By what mechanisms could tumor necrosis factor α antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?
Robinson, WH
Genovese, MC
Moreland, LW
ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : 1977 - 1983
[35] Mechanisms of tumor necrosis factor α action on neurodegeneration:: Interaction with insulin-like growth factor-1
Loddick, SA
Rothwell, NJ
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (17) : 9449 - 9451
[36] Behavior of Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptor 1/Tumor Necrosis Factor Receptor 2 System in Mononuclear Cells Recovered From Peritoneal Fluid of Women With Endometriosis at Different Stages
Salmeri, Francesca M.
Lagana, Antonio S.
Sofo, Vincenza
Triolo, Onofrio
Sturlese, Emanuele
Retto, Giovanni
Pizzo, Alfonsa
D'Ascola, Angela
Campo, Salvatore
REPRODUCTIVE SCIENCES, 2015, 22 (02) : 165 - 172
[37] Behavior of Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptor 1/Tumor Necrosis Factor Receptor 2 System in Mononuclear Cells Recovered From Peritoneal Fluid of Women With Endometriosis at Different Stages
Francesca M. Salmeri
Antonio Simone Laganà
Vincenza Sofo
Onofrio Triolo
Emanuele Sturlese
Giovanni Retto
Alfonsa Pizzo
Angela D’Ascola
Salvatore Campo
Reproductive Sciences, 2015, 22 : 165 - 172
[38] 4 DIFFERENT INTERLEUKIN-1 SPECIES SENSITIZE TO THE LETHAL ACTION OF TUMOR NECROSIS FACTOR
EVERAERDT, B
BROUCKAERT, P
SHAW, A
FIERS, W
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 163 (01) : 378 - 385
[39] Tumor necrosis factor-alpha induces leukocyte recruitment by different mechanisms in vivo and in vitro
Hickey, MJ
Reinhardt, PH
Ostrovsky, L
Jones, WM
Jutila, MA
Payne, D
Elliott, J
Kubes, P
JOURNAL OF IMMUNOLOGY, 1997, 158 (07): : 3391 - 3400
[40] Drug Insight: anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation
Johan F Skomsvoll
Marianne Wallenius
Hege S Koksvik
Erik Rødevand
Kjell Å Salvesen
Olav Spigset
Tore K Kvien
Nature Clinical Practice Rheumatology, 2007, 3 : 156 - 164

← 1 2 3 4 5 →